Drug Trial Radar · NCT05397938
Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis
Last checked: Nov 19, 2026Latest source record: May 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
231
Planned (sponsor's estimate)
Start
Jun 15, 2022
Primary completion
Jul 1, 2022
Study completion Jun 1, 2023
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, double-dummy, positive-controlled phase II interventional study designed to evaluate the efficacy and safety of JMT103 in the treatment of glucocorticoid induced osteoporosis patients. Patients will be enrolled and randomized to 3 treatment groups, JMT103 60 mg group (and alendronate sodium tablet placebo), JMT103 90 mg group (and alendronate sodium tablet placebo), and alendronate sodium 70 mg active comparator group (and JMT103 placebo). The primary outcome measure is percent change from baseline in lumbar bone mineral density (BMD) at 12 months of treatment. Besides, percent change of lumbar BMD at 6 months, percent change of total hip and femoral neck BMD at 12 months, and the incidence of new fracture at 12 months will be evaluated. Biomarkers of s-CTX and PINP, PK evaluation of JMT103 serum drug concentration, immunogenicity evaluation of ADA and Nab, and adverse events will be also collected.
Conditions
- Glucocorticoid Induced Osteoporosis
Interventions
JMT103Drug
JMT103, subcutaneous injection, once every 6 months (Q6M)
Alendronate sodiumDrug
Alendronate sodium tablet, once every week (QW)
JMT103 placeboDrug
JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)
Alendronate sodium placeboDrug
Alendronate sodium tablet placebo, once every week (QW)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change rate of lumbar bone mineral density (BMD) from baseline at 12 monthsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.